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Abstract. 
 
Ligand-stimulated activation of FGF recep-
tors (FGFRs) in skeletal muscle cells represses terminal 
myogenic differentiation. Skeletal muscle cell lines and 
subsets of primary cells are dependent on FGFs to re-
press myogenesis and maintain growth. To understand 
the intracellular events that transduce these signals, 
MM14 skeletal muscle cells were transfected with ex-
pression vectors encoding chimeric receptors. The 
chimeras are comprised of the PDGF 
 
b
 
 receptor 
(PDGF
 
b
 
R) extracellular domain, the FGFR-1 intra-
cellular domain, and either the PDGF
 
b
 
R or FGFR-1 
transmembrane domain. The chimeric receptors were 
autophosphorylated upon PDGF-BB stimulation and 
are capable of stimulating mitogen-activated protein ki-
nase activity. Activation of the tyrosine kinase domain 
of either chimera repressed myogenesis, suggesting in-
tracellular responses regulating skeletal muscle differ-
entiation are transduced by activation of the FGFR-1 
tyrosine kinase. Unexpectedly, we found that activation 
of either chimeric receptor failed to stimulate cellular 
proliferation. Thus, it appears that regulation of skeletal 
muscle differentiation by FGFs requires only activation 
of the FGFR tyrosine kinase. In contrast, stimulation of 
proliferation may require additional, as yet unidentified, 
signals involving the receptor ectodomain, the FGF 
ligand, and heparan sulfate either alone, or in combina-
tion.
Key words: skeletal muscle • differentiation • fibro-
blast growth factor • myogenesis • tyrosine kinase
 
S
 
keletal 
 
muscle differentiation is regulated by FGFs
in most skeletal muscle cell lines and in skeletal
muscle primary cultures (11, 19, 20, 25). In the de-
veloping chick, a population of muscle cells appears to be
dependent on FGFs, consistent with a requirement for
FGFs in regulating either the growth or differentiation of
skeletal muscle cells (unpublished data). As a model sys-
tem for investigating FGF-dependent skeletal muscle cells,
we study FGF signaling in the MM14 skeletal muscle cell
line, which is dependent on addition of exogenous FGFs
for maintenance of growth and repression of terminal dif-
ferentiation (20, 24). We have used the MM14 cell line to
demonstrate that FGF-mediated signals cannot be re-
placed by endogenous receptors, other growth factors, or
ectopically expressed growth factor receptors (16, 18, 20;
our unpublished data). To examine further the intracellu-
lar signals transduced upon stimulation of FGF receptor
(FGFR)-1
 
1
 
 in MM14 cells, we tested the capacity of two
receptor chimeras to repress myogenesis and to maintain
proliferation.
Numerous studies using receptor chimeras comprised of
extracellular and intracellular domains from different re-
ceptors have demonstrated that the intracellular and ex-
tracellular domains function independently of each other.
Intracellular signaling events mediated by orphan recep-
tors have been elucidated by constructing receptor chime-
ras containing a known ligand binding domains. Thus, chi-
meric receptors have proven useful for examining the
contribution of the intracellular domains of receptor ty-
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Abbreviations used in this paper
 
: BrdU, 5-bromo-2 deoxyuridine; CMV,
cytomegalovirus; ERK, extracellular-regulated kinase; FGFR, FGF re-
ceptor; MAPK, mitogen-activated protein kinase; MBP, myelin basic pro-
tein; MHC, myosin heavy chain; PDGF
 
b
 
R, PDGF 
 
b
 
 receptor; PR
 
tm
 
/FR1,
PDGF
 
b
 
R/FGFR-1 chimera with PDGF
 
b
 
R transmembrane domain; PR/
FR1
 
tm
 
, PDGF
 
b
 
R/FGFR-1 chimera with FGFR-1 transmembrane domain;
RT, reverse transcription; TPA, 12-
 
O
 
-tetra-decnoylphorbol-13-acetate.
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rosine kinases to signaling events. Receptor chimeras re-
tain the ligand binding and kinase activity of the extracel-
lular and cytoplasmic domains of the respective receptors
from which they were derived. For example, fusion of the
EGF receptor extracellular domain to the intracellular do-
mains of either the erbB receptor (30), the HER2 receptor
(17), or the insulin receptor (29), results in hybrid recep-
tors with tyrosine kinase activity that is upregulated by
EGF. These extensive studies suggest that signals initiated
by ligand binding are transduced from the extracellular
domain to the intracellular domain by similar mechanisms
for all receptor tyrosine kinases (36).
We previously demonstrated that the full-length PDGF
 
b
 
R
could not replace the requirement of FGF for repression of
skeletal muscle cell differentiation, despite the fact that cells
expressing the ectopic receptor activated intracellular signal-
ing pathways in response to PDGF-BB (16). To identify
FGFR domains involved in regulating skeletal muscle growth
and differentiation, we used two chimeras containing the
PDGF
 
b
 
R extracellular domain, the FGFR-1 intracellular do-
main, and a transmembrane domain from either FGFR-1 or
PDGF
 
b
 
R. Although both chimeras repressed skeletal mus-
cle differentiation, we were surprised to find that neither re-
ceptor chimera could support proliferation of skeletal muscle
cells. These data suggest that signaling pathways required
for proliferation cannot be activated by the hybrid receptors
and indicate that activation of the intracellular domain of
FGFR-1 at least in the context of the hybrid receptors is
capable of regulating differentiation of skeletal muscle cells,
but is insufficient to support proliferation.
 
Materials and Methods
 
Reverse Transcription (RT)-PCR Analysis of FGFRs
 
Total RNA was isolated from proliferating MM14 cells as previously de-
scribed (6). 5 
 
m
 
g of total RNA was added to reverse transcriptase buffer
(GIBCO-BRL, Gaithersburg, MD) containing 0.025 
 
m
 
g/
 
m
 
l Oligo (dT)
 
12–18
 
(GIBCO-BRL), 0.01 M DTT (GIBCO-BRL), 0.5 mM dNTP mix (GIBCO-
BRL), and 200 U of Superscript II reverse transcriptase (GIBCO-BRL).
The reaction was incubated at 42
 
8
 
C for 50 min. Non-reverse transcriptase
controls were carried out as described above with the exception of reverse
transcriptase addition. Mouse total RNA from an embryonic stem cell
mouse tumor was provided by Dr. J. Lee (University of Colorado, Boul-
der, CO).
PCR amplification was carried out by adding 2 
 
m
 
l of cDNA (or 0.5 
 
m
 
g
of plasmid DNA) to PCR buffer containing 0.25 mM each dNTP, 1.5 mM
MgCl
 
2
 
, 0.5 
 
m
 
M each of both forward and reverse primers for FGF recep-
tors 1, 2, 3, and 4 as previously described (9), and 5 U of Taq DNA poly-
merase (GIBCO-BRL). Each reaction was amplified for 35 cycles using
the following cycling parameters: denaturation at 94
 
8
 
C for 1 min, anneal-
ing at 50
 
8
 
C for 1 min, and elongation at 72
 
8
 
C for 1 min. After amplifica-
tion, each reaction was resolved on a 0.8% agarose gel containing ethid-
ium bromide and visualized with a UV transilluminator.
 
Cell Culture and Stable Transfection
 
Mouse MM14 skeletal muscle cells were cultured as described previously
(24). The pcDNA I expression vector (Invitrogen, San Diego, CA) encod-
ing a chimeric receptor consisting of the PDGF
 
b
 
R extracellular and trans-
membrane domains and the FGFR-1 intracellular domain (pcPR
 
tm
 
/FR1)
was obtained from Dr. M. Welsh (Uppsala University, Uppsala, Sweden)
(21). pcPR
 
tm
 
/FR1 was co-transfected into MM14 cells with a vector con-
taining the neomycin resistance gene (pKO-neo) by calcium phosphate–
mediated transfection (16). Cells expressing the highest level of chimeric
receptor were selected from neomycin-resistant cells by fluorescence-acti-
vated cell sorting using anti-PDGF
 
b
 
R mAb PR7212 (14), biotinylated
goat anti–mouse IgG, and FITC-avidin. The selected cells were subcloned
to derive cell lines that proliferated and differentiated in a manner similar
to parental MM14 cells.
MM14 cells overexpressing FGFR-1 were generated by co-transfecting
with a full-length mouse FGFR-1 cDNA under the control of a Moloney
SV-40 promoter and a hygromycin resistance gene under the control of a
cytomegalovirus (CMV) promoter (pHyg) at a 20:1 molar ratio (4 pmol/
0.2 pmol), respectively. After 24 h, 75 
 
m
 
g/ml hygromycin was added and
the cells were incubated for 12 d. Colonies resistant to hygromycin were
selected and pooled for analysis. The pooled clones were analyzed for
growth in FGF-2 and their differentiation capacity.
 
Transient Transfection Assay 
 
All transient transfections used a calcium phosphate precipitation method
(31). Briefly, MM14 cells stably expressing PR
 
tm
 
/FR1 were transiently
transfected with 1 
 
m
 
g of CMV-LacZ, 0.5 
 
m
 
g of an 
 
a
 
-cardiac actin lu-
ciferase reporter construct, and cultured without growth factor or with
FGF-2 or PDGF-BB for 36 h. The cells were harvested and assayed for lu-
ciferase and 
 
b
 
-galactosidase activities using the Tropix Dual Light assay,
using an Optocomp luminometer (MGM Instruments, Inc., Hamden, CT)
(16). Luciferase values were normalized to 
 
b
 
-galactosidase values to cor-
rect for variations in transfection efficiencies.
Parental MM14 cells were co-transfected with 
 
a
 
-cardiac actin lu-
ciferase, CMV-LacZ, and either pcPR
 
tm
 
/FR1, pBJ5PR/FR1
 
tm
 
, or a control
vector. pBJ5PR/FR1
 
tm
 
 is an expression construct containing the second
chimeric receptor gene (PR/FR1
 
tm
 
; provided by Dr. R. Bradshaw [Univer-
sity of California, Irvine, CA]; see Fig. 1 
 
A
 
) that encodes the extracellular
domain of the human PDGF
 
b
 
R fused to the transmembrane and intracel-
lular domains of the rat FGFR-1. The coding sequence was cloned into
the EcoRI site of pBJ5 in the sense orientation relative to the Sra pro-
moter (32). Cells were cultured with the indicated growth factor for 36 h
after osmotic shock, harvested, and then assayed for luciferase and 
 
b
 
-galac-
tosidase expression as described above.
 
Immunoblot Analysis
 
Anti-phosphotyrosine Blots. 
 
Proliferating MM14 cells were washed and in-
cubated in Ham’s F10C containing 2 mM CaCl
 
2
 
, supplemented with 2%
horse serum without FGF-2 for 3.5 h (proliferating cells) or 57.5 h (differ-
entiated cells). Cells were then stimulated with 2 nM PDGF-BB for 10
min where indicated. Cells were lysed in 25 mM Tris, pH 7.4, 50 mM
NaCl, 5 mM EDTA, 2 mM EGTA, 50 mM sodium pyrophosphate, 50 mM
NaF, 0.1 mM sodium orthovanadate, 1% Triton X-100, 2 
 
m
 
g/ml leupeptin,
2 
 
m
 
g/ml aprotinin, and 1 mM PMSF. Insoluble material was removed by
centrifugation and the protein content of each cell lysate measured using
the BCA protein assay (Pierce Chemical Co., Rockford, IL). Samples of
lysate containing 18 
 
m
 
g total protein were separated by SDS-PAGE on
7.5% acrylamide gels, and then transferred to an Immobilon membrane
(Millipore Corp., Bedford, MA). Tyrosine-phosphorylated proteins were
detected using the RC20-conjugated anti-phosphotyrosine mAb coupled
to HRP, and then developed for chemiluminescence according to the
manufacturer’s instructions (Transduction Laboratories, Lexington, KY).
 
Anti-PDGF
 
b
 
R Blots. 
 
For detection of expressed PR
 
tm
 
/FR1 chimeras,
cells were treated as described in the legend and cell lysates containing
60 
 
m
 
g total protein were loaded to each lane. The transferred protein blots
were incubated with an affinity-purified anti-PDGF
 
b
 
R mAb (2.5 
 
m
 
g/ml),
washed three times for 10 min, and then incubated with an anti–mouse
IgG conjugated to HRP. The blots were then developed for chemilumi-
nescent detection as described by the manufacturer (Amersham Corp.,
Arlington Heights, IL).
 
Cell Growth and Differentiation Assays
 
Immunohistochemical Assay for Myosin Heavy Chain (MHC).  
 
MM14 cells
stably expressing PR
 
tm
 
/FR1 were grown for 12 h in growth media (con-
tains F10C, 2 mM CaCl
 
2
 
, 15% horse serum) and increasing amounts of
FGF-2 (200 pM to 1.5 nM), incubated for 48 h, and then stained for MHC
as previously described (16).
 
DNA Synthesis Assay. 
 
DNA synthesis was assayed by [
 
3
 
H]thymidine in-
corporation into MM14 cells stably expressing PR
 
tm
 
/FR1 cells as previ-
ously described (24). Briefly, cells were plated in 24-well plates at 2,000
cells/well in growth media, with the indicated growth factor(s) for 18 h.
The cells were then incubated for 10 h with 2 mCi/ml [
 
3
 
H]thymidine (Du-
pont-NEN, Boston, MA), and the amount of [
 
3
 
H]thymidine incorporated
into DNA was quantitated by liquid scintillation counting. 
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Immunohistochemical Staining
 
MM14 cells were transiently transfected as described (13). 24 h after the
osmotic shock, 5-bromo-2 deoxyuridine (BrdU; Amersham Corp.) was
added to each plate to a final concentration of 10 
 
m
 
M. After 12 h of addi-
tional incubation, cells were fixed with 100% methanol and then treated
with 2 N HCl for 1 h at 37
 
8
 
C. Fixed cells were blocked in PBS containing
5% goat serum for 1 h at room temperature. The BrdU incorporated into
DNA was detected by staining with an anti-BrdU mAb (1:100; Develop-
mental Hybridoma Bank, Iowa City, IA). 
 
b
 
-Galactosidase was detected
by staining with an anti–
 
b
 
-galactosidase antibody (1:1,000; Boehringer
Mannheim Corp., Indianapolis, IN). Bound primary antibodies were visu-
alized with the appropriate immunoglobulin chain–specific goat anti–
mouse secondary antibodies (1:500; Southern Biotechnology Associates,
Inc., Birmingham, AL) conjugated to either Texas red (for BrdU) or
FITC (for 
 
b
 
-galactosidase).
 
MAPK Assays
 
Immune Complex Kinase Assay. 
 
MM14 cells stably expressing FGFR-1 or
the PR
 
tm
 
/FR1 chimera, at a density of 5 
 
3 
 
10
 
5
 
 cells per plate, were washed
three times with 5 ml of PBS, and then grown for 4 h in F10C containing
2 mM CaCl
 
2
 
, 2% horse serum without FGF-2. Cells were stimulated with ei-
ther 0.1 nM FGF-2, 2 nM PDGF BB, or 100 nM 12-
 
O
 
-tetra-decnoylphor-
bol-13-acetate (TPA) for 10 min. Cell lysates were prepared by washing the
plates in 4
 
8
 
C TBS, scraping the cells in homogenization buffer (50 mM Tris,
pH 7.4, 150 mM NaCl, 5 mM EDTA, 5 mM 
 
para
 
-nitrophenyl phosphate,
1 mM sodium orthovanadate, 10 mM tetra-sodium pyrophosphate decahy-
drate, 1 mM PMSF, 10 
 
m
 
g/ml aprotinin, 10 
 
m
 
g/ml leupeptin) in TBS, soni-
cating, and then centrifuging at 14,000 
 
g
 
 for 15 min at 4
 
8
 
C. Cell lysates were
adjusted to 1% Triton X-100, 0.5% sodium deoxycholate, and 0.1% SDS.
Protein A–Sepharose beads pre-loaded with anti-ERK1 polyclonal anti-
body (provided by Dr. C. Ashandel, Purdue University, West Lafayette,
IN) were incubated in cell lysates for 4 h at 4
 
8
 
C with rotation. The immune
complexes were washed three times in homogenization buffer supple-
mented with 1% Triton X-100, 0.5% sodium deoxycholate, and 0.1% SDS
and once in 20 mM Tris, pH 7. The immune complexes were then resus-
pended in 100 
 
m
 
l reaction buffer (12.8 mM Tris, pH 7.4, 5.5 mM 
 
para
 
-nitro-
phenyl phosphate, 51.5 mM MgCl
 
2
 
, 2 
 
m
 
g/ml myelin basic protein, 0.5 mCi/ml
[
 
g
 
-
 
32
 
P]ATP). The in vitro kinase reaction was carried out at 30
 
8
 
C for 30 min.
Reaction products were resolved by SDS-PAGE on a 10% polyacrylamide
gel. Phosphorylation of myelin basic protein was quantified using a Molecu-
lar Dynamics Storm PhosphorImager (Sunnyvale, CA).
 
elk Reporter Assay.  
 
MAPK (mitogen-activated protein kinase) activity
was also determined using Pathdetect ELK1 reporting system (Strat-
agene, La Jolla, CA) (35). MM14 cells were plated on six-well plates at a
density of 40,000 cells/well or on 24-well plates at a density of 8,000 cells/
well and cotransfected with 2.5 
 
m
 
g (500 ng for 24-well plate) pFR-Luc re-
porter vector, 200 ng (40 ng for 24-well plate) pFA–Elk1 vector, and 1 
 
m
 
g
(200 ng for 24-well plate) CMV–LacZ vector per well. 12–16 h after the
transfection cells were washed twice with PBS and incubated in media
containing 2.5% serum without FGF for 6 h. The cells were then left un-
treated, or stimulated with 0.1 nM FGF-2 or 1 nM PDGF. Cells were har-
vested and luciferase activity determined 6 h after mitogen stimulation.
Luciferase and 
 
b
 
-galactosidase activities were determined using the
Tropix Dual Light Assay (Tropix, Bedford, MA). Luciferase activity val-
ues were normalized to 
 
b
 
-galactosidase activity values to correct for trans-
fection efficiency.
 
High Level Expression Using a
Tetracycline-Repressible System
 
The DNA fragment encoding a dominant-negative FGFR-1 was sub-
cloned from pcDNFR1 (13) into the EcoRI/XbaI sites of pUHD 10-3 (28)
yielding dnFR1-tet. pUHD 10-3 is an expression vector under the control
of a tetracycline-repressible hybrid transcriptional activator constitutively
expressed from pUHD 15-1 (12). MM14 cells were co-transfected with 1 
 
m
 
g
of CMV-LacZ and 10 
 
m
 
g pUHD 15-1 and/or 10 
 
m
 
g of pUHC 13-3 (12) (a
luciferase reporter plasmid under the control of the transcriptional activa-
tor encoded by pUHD 15-1), and then cultured for 36 h in the presence or
absence of 1 
 
m
 
g/ml tetracycline. Cell lysates were prepared and assayed
for 
 
b
 
-galactosidase and luciferase activities as described previously using a
Tropix Dual Light assay (13). To test the effect of a dominant-negative
FGFR-1 on the activity of the PR/FR1
 
tm
 
 chimera, MM14 cells were tran-
siently transfected with 1 
 
m
 
g of CMV-LacZ, 5 
 
m
 
g of the 
 
a
 
-cardiac actin lu-
ciferase reporter construct, 10 
 
m
 
g pUHD 15-1, and combinations of pcPR/
FR1
 
tm
 
 and dnFR1-tet. After osmotic shock, cells were cultured for 36 h in
the absence of tetracycline, with or without the indicated additions of
FGF-2 or PDGF-BB. Cell lysates were then prepared and analyzed as pre-
viously described (13).
Equilibrium binding of 
 
125
 
I-labeled FGF-2 to intact MM14 and MM14-
FR1 cells. MM14 cells (5 
 
3 
 
10
 
5
 
) were plated in 35-mm dishes, and 4 h later
were incubated with 250 pM 
 
125
 
I-labeled FGF-2 (26) (7 
 
3 
 
10
 
3
 
 cpm/fmol) in
the presence or absence of 0.96 
 
m
 
M FGF-2 at 4
 
8
 
C. The cells were washed
three times with 2 ml F10C containing 25 mM Hepes, pH 7.4, and 0.2%
BSA. Cells were then washed twice with 1 ml the same buffer containing
2 M NaCl (low affinity) followed by two 1-ml washes with 20 mM NaAce-
tate, pH 4.0, containing 2 M NaCl and 0.2% BSA (high affinity). The
washes were pooled and counted in a Clinnigamma counter (LKB-Wallac,
Turku, Finland).
 
Results
 
We wanted to determine if activation of the FGFR ty-
rosine kinase is sufficient to mediate FGF-dependent bio-
logical activities. We chose to use the MM14 skeletal mus-
cle cell line as a model since these cells exhibit two distinct
FGF-dependent responses and serve as a model for a pop-
ulation of FGF-dependent myoblasts present in vivo. In
the absence of serum, FGFs repress terminal differentia-
tion independent of proliferation, whereas both serum and
FGFs appear to be required for stimulating proliferation
(7). Moreover, MM14 cells are absolutely dependent on
FGFs for repression of terminal differentiation and for
growth maintenance, since other growth factors are inca-
pable of replacing FGFs (23).
RT-PCR analysis of FGFRs in MM14 cells indicates
that the only detectable FGFR expressed is FGFR-1 (Fig.
1 
 
A
 
). In addition, we have previously demonstrated that
MM14 cells do not express the PDGF
 
b
 
R. Therefore, to as-
sess the role of the FGFR-1 tyrosine kinase in repression
of myogenesis and stimulation of proliferation in MM14
myoblasts, we examined the activity of two chimeric re-
ceptors containing the PDGF
 
b
 
R extracellular domain and
the FGFR-1 intracellular domain (Fig. 1 
 
B
 
).
MM14 cells stably expressing the PR
 
tm
 
/FR1 chimera
(Fig. 1 
 
B
 
) were selected as described in Materials and
Methods, and those clones exhibiting responses to FGF-2
similar to the parental cells were used for further studies.
MM14 cells expressing the wild-type PDGFbR (16) and
the PRtm/FR1 chimera were examined by Western blotting
with an anti-PDGFbR antibody. As expected, the chi-
meric receptor migrated more rapidly than the wild-type
PDGFbR expressed in human fibroblasts or ectopically
expressed in MM14 cells, because of the smaller size of the
intracellular domain of FGFR-1 (Fig. 2 A). As an initial
determinant of the capacity for the receptor chimera to
signal, the tyrosine kinase activity was examined by West-
ern blotting using anti-phosphotyrosine antibodies. Immu-
noblot analysis of proliferating and differentiated PDGF-
BB–treated MM14 cells stably expressing the PRtm/FR1
displayed a prominent phosphorylated product migrating
at z180 kD, the expected mass of the receptor chimera
(Fig. 2 B). The tyrosine phosphorylation occurring upon
FGF stimulation of the endogenous FGFR-1 is not detect-
able (data not shown), consistent with our previous obser-
vations (16). Presumably, this is due to the low number
of receptors per cell (z700). Tyrosine phosphorylated
FGFR-1 is observed only after ectopic overexpression (16).The Journal of Cell Biology, Volume 142, 1998 244
Next, we tested the ability of the PRtm/FR1 chimera to
regulate skeletal muscle differentiation using three inde-
pendent assays: (1) analysis of muscle-specific reporter
gene expression; (2) the presence of muscle-specific MHC
protein; and (3) fusion into multinucleated myotubes. Ad-
dition of PDGF-BB to MM14 cells stably expressing the
PRtm/FR1 chimera inhibited the expression of a muscle-
specific reporter gene (Fig. 3 A), and blocked differentia-
tion as judged by either myosin staining (Fig. 3 B) or the
relative number of nuclei present in multinucleated myo-
tubes (data not shown). These data were consistent with
those observed in one other stable subclone (data not
shown).
It is possible, although unlikely, that the biological activ-
ity believed to be mediated by the PRtm/FR1 receptor chi-
mera is an artifact occurring as a result of transfection, se-
lection, or isolation of the two stable subclones. Therefore,
we analyzed the ability of the PRtm/FR1 chimera to re-
press differentiation in transiently transfected cells. In
addition, we examined the activity of a similar receptor
chimera (PR/FR1tm; see Fig. 1 A), which contains the
FGFR-1 transmembrane domain rather than the PDG-
FbR transmembrane domain. Cells assayed for muscle-
specific reporter gene activity after transient transfection
with either chimeric receptor construct and a skeletal mus-
cle–specific reporter revealed that both the PRtm/FR1
(Fig. 4 A) and the PR/FR1tm (Fig. 4 B) chimeras similarly
inhibited muscle-specific reporter gene transcription in the
presence of PDGF-BB. Note that the PR/FR1tm chimera
inhibited the endogenous response to FGF-2 (Fig. 4 B).
When FGF is removed from MM14 cells in the presence
of serum, the cells withdraw from the cell cycle and ex-
press muscle-specific gene products (7). Since FGFs may
be required for proliferation of MM14 cells and for repres-
sion of differentiation, we wanted to determine if activa-
tion of the receptor chimeras was sufficient to maintain
cell proliferation as well as to repress differentiation.
Figure 2. Chimeric receptor expression and activity. (A) Western
blot analysis of the PDGFbR and the PRtm/FR1 chimera. MM14
cells stably expressing the introduced PDGFbR (lanes 1 and 2),
human fibroblasts expressing endogenous PDGFbR (lanes 3 and
4), MM14 cells expressing the PRtm/FR1 chimera (lanes 5 and 6),
and untransfected MM14 cells (lanes 7 and 8) were separated by
SDS-PAGE, blotted, and then stained with an anti-PDGFbR
mAb (lanes 1–8). The solid arrowhead indicates the migration of
the PRtm/FR1 chimera and the open arrowhead indicates the mi-
gration of the PDGFbR. (B) PDGF-BB–stimulated tyrosine
phosphorylation in MM14 cells stably expressing PRtm/FR1. Pro-
liferating (lanes 1 and 2) and differentiated (lanes 3 and 4) cells
were left unstimulated (lanes 1 and 3) or were stimulated with 2
nM PDGF-BB (lanes 2 and 4) for 10 min. An anti-phosphoty-
rosine immunoblot analysis of equal amounts of detergent-solu-
bilized cell extracts is shown. The arrow indicates the position of
migration of the tyrosine-phosphorylated chimeric receptor after
PDGF-BB stimulation of both proliferating and differentiated
cells. The migration of molecular weight markers is indicated on
the left.
Figure 1. FGFR expression and receptor chimeras. (A) RT-PCR
analysis of FGFR expression in MM14 cells. RT-PCR of total
RNA from MM14 cells demonstrates that these cells detectably
express only FGFR-1. RT-PCR analysis included either RNA
prepared from MM14 cells (lanes 2–5); plasmid DNAs for
FGFR-1 (lane 6), FGFR-2 (lane 7); total RNA prepared from
embryonic stem cell tumors (lanes 8 and 9); and a no DNA con-
trol (lanes 10–13). Lanes 1 and 14 contain a 1-kb ladder. Specific
primers for FGFR-1, FGFR-2, FGFR-3, and FGFR-4 were used
as indicated in the figure. (B) The biological activities of four dif-
ferent receptors were examined in MM14 cells and include
FGFR-1, PDGFbR, the PRtm/FR1 chimera containing the PDG-
FbR extracellular (light gray), transmembrane (white) domains,
the FGFR-1 intracellular (dark gray) domain, and the PR/FR1tm
chimera containing the PDGFbR extracellular domain (light
gray), the FGFR-1 transmembrane (black), and intracellular do-
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MM14 cells stably expressing the PRtm/FR1 chimera were
tested for the ability to synthesize DNA upon addition of
PDGF-BB. An analysis of DNA synthesis indicated that
these cells could not incorporate [3H]thymidine in the
presence of 1 nM PDGF-BB and 15% serum (Fig. 5 A).
Higher concentration of PDGF-BB up to 50 nM also
failed to elicit DNA synthesis (data not shown). More-
over, the kinetics of cell cycle withdrawal are indistin-
guishable for PRtm/FR1-expressing cells in the presence or
absence of PDGF-BB (Fig. 5 B). Thus, the receptor chi-
mera does not appear to be capable of affecting either
DNA synthesis or cell growth. It is possible that the PRtm/
FR1 chimera is defective in a subset of signaling events.
However, a different receptor chimera containing the
FGFR-1 transmembrane domain would not necessarily be
expected to exhibit a similar signaling defect. To test
whether or not both receptor chimeras exhibited similar
deficiencies in signaling, MM14 cells transiently trans-
fected with an expression vector encoding the PR/FR1tm
chimera were examined for their ability to synthesize
DNA upon addition of PDGF-BB. Cells transiently co-
transfected with PR/FR1tm and LacZ expression vectors
were allowed to incorporate BrdU, and were immu-
nostained for BrdU and b-galactosidase. 10–15% of the
cells stained positive for b-galactosidase activity, consis-
tent with previously published data on transfection effi-
ciencies (13). In cells ectopically expressing the PR/FR1tm
chimera, BrdU incorporation was not seen in the absence
of growth factors and in the presence of added PDGF-BB.
However, in contrast to the PR tm/FR1 chimera, FGF-2 ad-
dition to cells expressing the PR/FR1tm chimera does not
promote DNA synthesis (Fig. 6), suggesting that the inclu-
sion of the FGFR-1 transmembrane domain interferes
with signaling from the endogenous FGFR-1. The non-
transfected cells (b-galactosidase–negative cells) did not
incorporate BrdU in the absence of FGF-2 (data not
shown). Expression of either receptor chimera appears to
be incapable of stimulating DNA synthesis in the presence
of PDGF-BB and 15% serum. No significant BrdU incor-
poration above control levels was seen in PDGF-BB–
treated cells negative for b-galactosidase, indicating the
absence of PDGFRs and a PDGF response in the parental
MM14 cell population. Quantitative analysis of transfected
cells revealed that .80% of the PR/FR1tm- and PR tm/FR1-
expressing cells failed to synthesize DNA upon addition of
PDGF-BB (Fig. 6). Thus, both receptor chimeras act simi-
larly in their ability to transduce only a portion of the FGF
signal, suggesting that activation of the intracellular
Figure 3. Stably expressed PRtm/FR1 chimeric receptors repress
differentiation. (A) PDGF-BB represses skeletal muscle-specific
gene expression in PRtm/FR1 cells. MM14 cells stably expressing
PRtm/FR1 were transiently transfected with a differentiated mus-
cle-specific gene reporter (a-cardiac actin luciferase). Cells trans-
fected with the empty vector (white) or the PRtm/FR1 expression
construct (gray) were left untreated (Control), treated with FGF-2,
or treated with PDGF-BB. Data are represented as a percent of
the control activity. Error bars represent the standard deviation
of triplicate analyses. (B) PDGF-BB represses skeletal muscle
differentiation in MM14 cells stably expressing the PRtm/FR1 chi-
meric receptor. MM14 cells transfected with a control vector (the
expression plasmid minus the receptor chimera cDNA; white) or
the PRtm/FR1 chimera (gray) exhibit a low number of myosin
positive cells in the presence of FGF. In the absence of growth
factors, cells were maintained in the presence of anti-PDGFbR
and anti–FGF-2 antibodies as previously described (16) to reduce
stimulation from serum-derived PDGF-BB and residual FGF-2,
respectively. Maximum levels of MHC-positive cells are observed
in 2% horse serum in the absence of FGF. Each data point is the
average of duplicate plates from a representative experiment
with an average of 1,500 cells scored for each plate. The number
of myosin-positive cells in the presence of FGF (gray bar, 15%
HS 1 FGF) was 0% and thus is too low a value to be observable
on the histogram.
Figure 4. Transiently expressed PRtm/FR1 and PR/FR1tm recep-
tor chimeras repress differentiation. (A) PDGF-BB inhibits myo-
genic differentiation in cells transiently transfected with an ex-
pression vector encoding the PRtm/FR1 receptor chimera. MM14
cells were transfected with expression vectors encoding the PRtm/
FR1 receptor chimera (gray) or a control vector (white), a mus-
cle-specific luciferase reporter and a constitutively active LacZ
reporter. Cultures were left untreated or fed at 12-h intervals
with increasing concentrations (1–2 nM) of FGF-2 or PDGF-BB.
At 36 h, the cells were harvested and assayed for luciferase and
b-galactosidase activity. (B) PDGF-BB inhibits myogenic differ-
entiation in cells transiently transfected with an expression vector
encoding the PR/FR1tm receptor chimera. MM14 cells were
transfected with expression vectors encoding the PR/FR1tm re-
ceptor chimera (black) or a control vector (white), a muscle-spe-
cific luciferase reporter and a constitutively active LacZ reporter.
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FGFR-1 tyrosine kinase in the context of the chimeric re-
ceptor is insufficient to mediate DNA synthesis or cell di-
vision.
It is possible that the receptor chimeras are affecting the
mRNA stability, transport, or translation of the muscle-
specific reporter gene (see Fig. 4) and thus, the receptor
chimeras might not actually be inhibiting skeletal muscle
differentiation. Therefore, we confirmed that the chimeric
receptors were capable of repressing myogenic differentia-
tion. Skeletal muscle cells transiently transfected with PR/
FR1tm and LacZ expression constructs were examined for
the number of nuclei in myotubes. In the presence of
PDGF-BB, cells expressing the PR/FR1tm chimera (b-galac-
tosidase–positive cells), were not present in myotubes,
similar to that of cells cultured in FGF-2 (data not shown).
In co-transfected cells, nuclei were present in myotubes in
the absence of PDGF-BB, (data not shown).
We have previously demonstrated that activation of
FGF receptors in MM14 cells weakly activates ERKs (16).
We thus examined the capacity of the receptor chimeras to
activate MAPKs using two independent assays. The PRtm/
FR1 chimera activates ERK1/2 (Fig. 7 A) and both recep-
tor chimeras, as well as the endogenous FGFR-1 are capa-
ble of stimulating MAPK activity as determined by an elk
reporter gene assay (Fig. 7 B). In this assay, cells express-
ing the receptor chimeras exhibit high basal activation of
the elk reporter (Fig. 7 B), which may be due to receptor
activation by residual PDGF-BB present in the serum or
auto-activation of receptors resulting from the high level
of receptor chimera expressed.
Figure 5. Chimeric receptors fail to stimulate DNA synthesis or
cell growth. (A) PDGF-BB does not block cell cycle exit in
MM14 cells stably expressing the PRtm/FR1 receptor chimera.
Cells expressing PRtm/FR1 were cultured in the indicated concen-
trations of either FGF-2 (h) or PDGF-BB (d) for 18 h. [3H]Thy-
midine was then added and the amount of [3H]thymidine incor-
porated was determined after 10 h. Error bars represent the
standard deviation of triplicate points. (B) PDGF-BB does not
stimulate cell growth in MM14 cells stably expressing the PRtm/
FR1 receptor chimera. Equal numbers of MM14 cells expressing
the PRtm/FR1 receptor were grown for 24 h, and then switched to
media and 15% horse serum containing no growth factors (e), or
fed at 12-h intervals with increasing concentrations (0.5–2 nM) of
FGF-2 (h), or PDGF-BB (d). At the indicated times the number
of cells per 100-mm2 plate were scored.
Figure 6. Single cell analysis of transiently expressed chimeric re-
ceptors. Quantitative analysis of BrdU incorporation. MM14 cells
transiently co-transfected with an empty expression vector, or
PRtm/FR1, or PR/FR1tm, and a CMV-LacZ expression vector
were either left untreated (white), or treated with 200 pM FGF-2
(gray), or 1 nM PDGF-BB (black) after transfection. b-Galac-
tosidase–positive cells were scored for BrdU incorporation and
the percent of BrdU-positive cells plotted. A minimum of 200
b-galactosidase–positive cells were scored for each coverslip. One
representative experiment is shown. The experiment was re-
peated with similar results.
Figure 7. ERK activation by receptor chimeras in MM14 cells.
(A) Proliferating MM14 cells stably expressing PRtm/FR1 were
starved and then stimulated for 10 min as indicated. Cell lysates
were prepared and ERK1/2 proteins were immunoprecipitated.
Immune complexes were subjected to an in vitro kinase assay and
the reaction products resolved by SDS-PAGE. Incorporation of
32P was quantified by phosphoimage analysis. The inset illustrates
a representative example from the gel analysis (N, F, P, and T
correspond to None, FGF-2, PDGF-BB, and TPA, respectively.)
Error bars represent the standard deviation of three independent
samples. (B) Cells transiently expressing the PR/FR1tm chimera
activate an elk reporter gene. MM14 cells transiently co-trans-
fected with the PR/FR1tm chimera, an elk reporter, and a consti-
tutively expressed LacZ construct were either left untreated
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One potential explanation for the ability of the receptor
chimeras to repress differentiation could result from auto-
crine production and release of endogenous FGFs, a
mechanism that we have shown to be able to replace the
activity of exogenously applied FGFs (13). To test this hy-
pothesis, we chose to block any potential FGFR-mediated
signaling by exploiting a tetracycline-responsive system to
induce high level expression of a truncated FGFR-1 (12).
The use of this system is required to achieve high level ex-
pression of the truncated FGFR-1 necessary to block en-
dogenous FGFR-1 signaling with relatively low amounts
of expression vector used for the transient transfection as-
says. We have shown that ectopic expression of a vector
encoding a truncated FGFR1 blocks the activity of exoge-
nously applied FGFs and endogenously expressed FGFs in
MM14 cells (13). To test the extent of induction using the
tetracycline system, MM14 cells were transiently trans-
fected with expression vectors encoding the luciferase
gene under the control of the tetracycline activator, the
tetracycline activator plasmid, and a constitutively active
LacZ expression vector. Luciferase activity was induced
several hundred–fold upon removal of tetracycline (Fig. 8
A). The presence or absence of a wide concentration range
of tetracycline had no effect on myogenic differentiation
or the ability of FGF to promote proliferation and repress
differentiation (data not shown). We then constructed a
dominant-negative FGFR expression plasmid (dnFR1-tet)
that could be induced using the tetracycline activator.
MM14 cells were then transiently transfected with either
dnFR1-tet, pBJ5PR/FR1tm, or both along with the tetracy-
cline activator plasmid, the muscle-specific luciferase re-
porter, and the constitutively active LacZ expression vec-
tor. Muscle-specific luciferase reporter assays demonstrate
that the action of FGF-2 is blocked upon transfection with
the dnFR1-tet construct (Fig. 8 B). However, the PR/
FR1tm chimera is capable of signaling in the presence or
absence of the dnFR1-tet construct (Fig. 8 B). Thus,
PDGF-dependent signaling mediated by the receptor chi-
meras is likely to be direct and is not mediated via produc-
tion and release of endogenous FGFs.
A second interpretation that could account for the in-
ability of the receptor chimera to transduce signals for cel-
lular proliferation might be an overstimulation of ERK1/2.
The endogenous FGFR-1 weakly stimulates ERK1/2 (see
Fig. 7) and ectopic overexpression of the receptor chime-
ras stimulates ERK1/2 to a greater extent (see Fig. 7).
Therefore, we isolated MM14 cells that stably overexpress
FGFR-1 (MM14-FR1) at levels 7- to 10-fold higher than
parental cells (Fig. 9 A). Consistent with the elevated lev-
els of FGFR-1 in MM14-FR1 cells, activation of ERK1/2
was also significantly increased (Fig. 9 B). However, the
dose-responses for FGF-2 stimulation of DNA synthesis in
MM14 parental cells and MM14-FR1 were indistinguish-
able, suggesting that the increase in ERK1/2 activity did
not affect signaling for cellular proliferation (Fig. 9 C).
Discussion
To identify specific biological responses mediated by the
FGFR-1 tyrosine kinase domain in skeletal muscle cells,
we used receptor chimeras comprised of the PDGFbR ex-
tracellular and FGFR-1 intracellular domains. We previ-
ously demonstrated that PDGFbRs are not present in
MM14 cells and that the activated PDGFbR has no de-
tectable effect on skeletal muscle cell proliferation or dif-
ferentiation (16). Thus, it is an ideal candidate for use in
construction of chimeric receptors with FGFR-1 domains
and subsequent analysis of receptor domains necessary for
signaling. Two distinct receptor chimeras were tested that
contained the transmembrane domain of FGFR-1 or the
PDGFbR. The genetic defects in skeletal dysplasias and
craniosynostosis can result from mutations in the FGFR-3
and FGFR-2 transmembrane domains, respectively (8).
Figure 8. Signaling mediated by the chimeric receptors is not me-
diated via an indirect autocrine FGF response. (A) Luciferase ex-
pression is induced nearly 300-fold in MM14 cells transiently
transfected with both the tetracycline activator construct and the
tetracycline activator–responsive luciferase reporter construct
relative to cells transfected only with the reporter construct.
MM14 cells were transiently co-transfected with a LacZ expres-
sion construct (CMV-LacZ) along with the tetracycline activator
construct (Activator), the luciferase reporter construct under the
control of the tetracycline activator (Luciferase), and then cul-
tured in the presence or absence of tetracycline (Tet; 1 mg/ml) for
36 h, harvested and then assayed for luciferase and b-galactosi-
dase activities. (B) MM14 cells were transiently co-transfected
with a muscle-specific luciferase reporter gene, CMV-LacZ, the
tetracycline activator construct and/or dnFR1-tet, which encodes
a dominant-negative FGFR-1 mutant under the control of the
tetracycline activator, and where indicated, PR/FR1tm. All cul-
tures were maintained in the absence of tetracycline and received
either no treatment, FGF-2 (1 nM), or PDGF-BB (2 nM). After
36 h, the luciferase and b-galactosidase activities were measured
to determine muscle-specific promoter activity. Error bars repre-
sent the standard deviation of triplicate points. All data shown
are from cells incubated in the absence of tetracycline.The Journal of Cell Biology, Volume 142, 1998 248
These mutations lead to ligand-independent receptor
activity or ligand-dependent receptor hyperactivity (8). Thus,
it was important to determine if the transmembrane domain
replacement would affect chimeric receptor signaling.
Unexpectedly, we found that both PDGFbR/FGFR-1
chimeras were capable of complementing only part of the
function of the endogenous FGFR-1. The chimeric recep-
tors were capable of mediating a complex biological re-
sponse—repression of skeletal muscle differentiation. In
contrast to the endogenous FGFR-1 signaling, neither re-
ceptor chimera supported cell proliferation. It is unlikely
that the extracellular domain of the PDGFbR and binding
to PDGF-BB indirectly inhibits FGF signaling since we
have shown previously that expression of the full-length
PDGFbR had no effect on FGF signaling through endoge-
nous FGFR-1 (16). Interestingly, we noted that the chi-
mera that contained the PDGFRb transmembrane do-
main did not affect signaling from the endogenous FGFR-1,
whereas the chimera containing the FGFR-1 transmem-
brane domain acted as a dominant-negative FGFR-1 mu-
tant. While we do not understand the molecular basis for
these differences, it is known that mutations in FGFR (8)
and neu (2, 3) transmembrane domains result in constitu-
tively active receptors. Thus, alterations in receptor re-
gions juxtaposed to the transmembrane domain may alter
or inhibit receptor signaling. Though the chimeric recep-
tors contain different transmembrane domains both yielded
identical biological activities, suggesting that FGF regu-
lates skeletal muscle proliferation and differentiation via
different signaling systems. We propose that activation of
the FGFR-1 receptor tyrosine kinase alone is sufficient to
repress myogenesis. This is in contrast to a number of re-
cent reports that implicate FGF and intracellular FGF
transport in the biological activity mediated by FGFR-1.
In these studies, intracellular transport of FGF ligands
was reported to stimulate DNA synthesis independent of
FGFR tyrosine kinase activation (33, 34). Our results indi-
cate that regulation of skeletal muscle differentiation ap-
pears to require only activation of the FGFR-1 tyrosine ki-
nase and does not appear to require intracellular transport
of the FGF ligand nor activation of intracellular events by
the ligand.
Since ectopically expressed FGF-1 and FGF-2 repress
myogenesis and stimulate proliferation (13), it is possible
that the chimeric receptors signal via autocrine-stimulated
release of FGFs, that act on the endogenous FGFR-1. To
ensure that activation of the FGFR-1 tyrosine kinase was
not signaling via autocrine release or production of FGFs,
we used a tetracycline-responsive system to overexpress
the dominant negative FGFR-1 mutant in cells expressing
chimeric receptors. The mutant FGFR-1 blocked all sig-
naling from the endogenous FGFR-1 but did not affect re-
pression of differentiation mediated by the chimeric re-
ceptor. Alternatively, the level of activation of MAPKs
may be critical for distinguishing between proliferation
and differentiation signals. It is possible that overexpres-
sion of the receptor chimeras, which led to robust MAPK
activation inhibited or altered signals that lead to prolifer-
ation. Therefore, we selected cells that overexpressed
FGFR-1 and examined FGF-2–induced stimulation of
ERK1/2 and FGF-2 stimulation of mitogenesis. Although
FGF-2 addition significantly increased ERK1/2 activation,
we observed no detectable differences in the mitogenic re-
sponses to FGF-2 between the FGFR-1–overexpressing
cells and the parental cell line.
Consistent with reports suggesting that signaling events
in addition to activation of FGFR kinases are necessary to
mediate cellular proliferation by the FGFs, we observed
that PRtm/FR1 and PR/FR1tm were incapable of maintain-
ing cellular proliferation or initiating DNA synthesis. It is
possible that the extracellular domain of FGFR, FGF,
heparan sulfate proteoglycan, or a combination of these is
required for DNA synthesis and cell proliferation. We fa-
vor a hypothesis that involves FGF, the ectodomain of the
FGFR-1, or both, in transducing intracellular signals in-
volved in stimulating cellular proliferation. It is tempting
to speculate that the ectodomain of the receptor is re-
quired for intracellular transport of the FGF ligand, which
then is involved in stimulating DNA synthesis. This hy-
pothesis is consistent with several reports suggesting an al-
Figure 9. Overexpression of FGFR-1 enhances ERK1/2 stimulation but fails to affect proliferation. MM14 cells were stably transfected
with an FGFR-1 expression vector. MM14 cells overexpressing FGFR-1 (black) were compared with parental cells (white) for FGF-2
binding (A), ERK1/2 activity (B), and DNA synthesis (C). (A) Equilibrium binding was performed using 125I-labeled FGF-2 as de-
scribed in Materials and Methods. High and low affinity sites were revealed by washing intact cells with high salt or high salt/low pH
buffers, respectively. (B) ERK 1/2 activity was determined using myelin basic protein as a substrate for parental (white) and FGFR-1
overexpressing cells (black). Cells were stimulated with DMSO (none), 100 pM FGF-2, or 100 nM TPA for 10 min and then assayed as
described in Materials and Methods. The reaction products were resolved by SDS-PAGE and radiolabeled MBP quantified by phos-
phoimage analysis. The values for DMSO treatment were normalized to 1.0 to compare the two cell lines. Error bars indicate standard
deviation. (C) DNA synthesis was examined in parental MM14 cells (h) and MM14-FR1 cells incubated (r) with increasing concentra-
tions of FGF-2 using a cell proliferation assay as described in Materials and Methods. The results are the representative of a single ex-
periment. Each determination was repeated twice with similar results.Kudla et al. Distinct FGFR-1 Signals Regulate Differentiation and Proliferation 249
ternate signaling role for FGF ligands (1, 4, 5, 15, 33, 34)
and for the involvement of FGFR-1 in intracellular trans-
port of the FGF ligand (27).
We hypothesize that it is unlikely that the receptor chi-
meras are compromised in their ability to activate their re-
spective tyrosine kinase domains. While we cannot com-
pare directly tyrosine phosphorylation of the endogenous
FGFR-1 with the ectopically expressed chimeric receptors,
we did compare activation of MAPKs and inhibition of
skeletal muscle gene expression by both chimeric recep-
tors and the endogenous FGFR-1. We would expect to see
defects in signaling that would be distinct for each recep-
tor if the construction of receptor chimeras affected acti-
vation of the FGFR-1 tyrosine kinase, yet both chimeric
receptors stimulate MAPK activity. However, activation
of the receptor chimeras may differ subtly from activation
of a wild-type receptor creating a partially defective recep-
tor that is not capable of stimulating cell proliferation. Al-
though we tested to determine if differences in ERK1/2
activation were responsible, differences in activation levels
of other signal transducers could be involved. In other ex-
periments, we have constructed a constitutively active
FGFR-1 receptor chimera. Preliminary data indicate that
the behavior of this receptor is identical to the PDGFbR/
FGFR-1 chimeras as it is capable of repressing myogenesis
but cannot support proliferation. Whereas these experi-
ments do not prove an involvement of the ectodomain,
ligand, or additional components in FGFR-1 signaling,
they do demonstrate that the signaling events required for
repression of myogenesis and stimulation of proliferation
by FGFR-1 are distinct and separable. Remarkably, both
receptor chimeras used in our experiments were fully ca-
pable of repressing skeletal muscle differentiation, a com-
plex biological response whose signaling pathways are not
understood.
The involvement of intracellular FGFR-1 phosphoty-
rosines in FGFR-1 signaling has been questioned since
mutagenesis of all but two intracellular phosphotyrosines
(Y654 and Y655), required for catalytic activity, had no ef-
fect on FGFR-1 signaling (22). These data suggest that the
molecular mechanisms used by FGFR-1 to transduce in-
tracellular signals may differ significantly from those de-
scribed for other tyrosine kinase receptors. Recently, a
similar conclusion was reached for the muscle-specific re-
ceptor tyrosine kinase (MuSK) receptor (10). Chimeric re-
ceptors comprised of the trkC extracellular domain and
the MuSK intracellular domain, were incapable of acetyl-
choline receptor clustering, despite the activation of intra-
cellular signaling by the chimera (10).
By determining which biological activities are mediated
by the FGFR-1 tyrosine kinase, we have shown that two
FGF-dependent cellular activities in a single cell type ap-
pear to be independently mediated by distinct signaling
mechanisms that result from ligand binding to FGFR-1.
Further analysis of the signaling pathways stimulated by
the chimeric receptors will provide us with a powerful tool
in the delineation if signaling pathways mediating the re-
pression of skeletal muscle differentiation. Domain-swap-
ping experiments with intracellular regions of the PDG-
FbR and mutagenesis of the intracellular FGFR-1
domains are likely to identify critical regions of the FGFR-1
receptor involved. In addition, we can now use these chi-
meric receptors for rescue studies to attempt to identify
the signaling mechanisms necessary for stimulation of cel-
lular proliferation. Identification of these latter pathways
is likely to further our understanding of FGFR signaling
and identify the molecular mechanisms involved in the ac-
tivation of intracellular signaling events that generate spe-
cific biological responses.
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